Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Topics Community

Article

Pharmacogenetics and pharmacokinetics of tamoxifen in a Zimbabwean breast cancer cohort.

British journal of clinical pharmacology - 1 Oct 2023

Mbavha Bianza Tinotenda, Thelingwani Roslyn Stella, Chikwambi Zedias, Nyakabau Anna Mary, Masimirembwa Collen

Abstract excerpt

Tamoxifen is the most used hormonal therapy for oestrogen receptor-positive breast cancer. CYP2D6 is the main enzyme in the metabolic pathway of tamoxifen to endoxifen. Variations in endoxifen plasma concentrations are associated with CYP2D6 polymorphisms. This study aimed to determine the association between the CYP2D6 polymorphisms and endoxifen plasma concentrations in a cohort of Zimbabwean breast cancer...

Topics

Join the communities discussing this publication.

Antineoplastic Agents, Hormonal
Breast Neoplasms
Chromatography, Liquid
Cytochrome P-450 CYP2D6
Pharmacogenetics

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Tandem Mass Spectrometry

Source

Open in PubMed Open full text

Identifiers

PMID: 37337448
DOI: 10.1111/bcp.15827
PMCID: PMC10529681

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 31 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacogenetics and pharmacokinetics of tamoxifen in a Zimbabwean breast cancer cohort.PMID 37337448Read ↗

Pharmacogenetics and Pharmacokinetics of Tamoxifen in a Zimbabwean breast cancer cohortSemantic proximity Read ↗

CYP2D6 Genotype Predicts Plasma Concentrations of Tamoxifen Metabolites in Ethiopian Breast Cancer PatientsSemantic proximity Read ↗

CYP2D6 and Endoxifen in Tamoxifen Therapy: A Tribute to David A. Flockhart.Semantic proximity Read ↗

Clinical pharmacokinetics and pharmacogenetics of tamoxifen and endoxifenSemantic proximity Read ↗

CYP2D6 Genotyping for Personalized Therapy of Tamoxifen in Indonesian Women with ER+ Breast CancerSemantic proximity Read ↗

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy.Semantic proximity Read ↗

<i>CYP2D6</i> Genotyping for Personalized Therapy of Tamoxifen in Indonesian Women with ER+ Breast CancerSemantic proximity Read ↗

Impairment of endoxifen formation in tamoxifen-treated premenopausal breast cancer patients carrying reduced-function CYP2D6 alleles.Semantic proximity Read ↗

A Genome-Wide Association Study of Endoxifen Serum Concentrations and Adjuvant Tamoxifen Efficacy in Early-Stage Breast Cancer Patients.Semantic proximity Read ↗

Important and critical scientific aspects in pharmacogenomics analysis: lessons from controversial results of tamoxifen and CYP2D6 studies.Semantic proximity Read ↗

Clinical CYP2D6 Genotyping to Personalize Adjuvant Tamoxifen Treatment in ER-Positive Breast Cancer Patients: Current Status of a ControversySemantic proximity Read ↗

Clinical Trial: CYP2D6 Related Dose Escalation of Tamoxifen in Breast Cancer Patients With Iranian Ethnic Background Resulted in Increased Concentrations of Tamoxifen and Its MetabolitesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.